Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jinhai Medical TechnologyHKSE:02225 -7.14%61 PB Ratio is 100.75 as of Sep. 10, 2026, which is 443% above its 10-year median of 18.57. GuruFocus rates HKSE:02225 with a GF Score™ of 61/100 and a GF Value™ of HK$1.41 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 533 Conglomerates companies, Jinhai Medical Technology ranks worse than 99.81% on this metric.
Jinhai Medical Technology Ltd stock PB Ratio (=108.5) is close to 10-year high of 111.64.
The historical rank and industry rank for Jinhai Medical Technology's PB Ratio or its related term are showing as below:
HKSE:02225'
s PB Ratio Range Over the Past 10 Years
Min: 3.86 Med: 18.57 Max: 111.64
Current: 100.75
During the past 12 years, Jinhai Medical Technology's highest PB Ratio was 111.64. The lowest was 3.86. And the median was 18.57.
HKSE:02225's PB Ratio is ranked worse than 99.81% of 533
companies
in the Conglomerates industry
Industry Median: 1.06
vs HKSE:02225: 100.75
During the past 12 months, Jinhai Medical Technology's average Book Value Per Share Growth Rate was 65.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 26.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 11.50% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Jinhai Medical Technology was 63.60% per year. The lowest was -6.10% per year. And the median was 13.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Jinhai Medical Technology PB Ratio Related Terms
Jinhai Medical Technology PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Conglomerates subindustry, Jinhai Medical Technology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jinhai Medical Technology PB Ratio vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Jinhai Medical Technology's PB Ratio distribution charts can be found below:
* The bar in red indicates where Jinhai Medical Technology's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Jinhai Medical Technology (HKSE:02225) has a PB Ratio of 100.75 as of Sep. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jinhai Medical Technology and its competitors. This is 443% above median its historical median of 18.57. Over the past decade, Jinhai Medical Technology's PB Ratio has ranged from 3.86 to 111.64. According to the industry distribution chart, Jinhai Medical Technology ranks #532 out of 533 companies in the Conglomerates industry, placing it in the top 99.8%.
Is Jinhai Medical Technology's PB Ratio too high?
Jinhai Medical Technology's current PB Ratio of 100.75 is 443% above median its 10-year median of 18.57. Over the past 10 years, this metric has ranged from a low of 3.86 to a high of 111.64. The Conglomerates industry median PB Ratio is 1.06. Jinhai Medical Technology's value of 100.75 is 9404.7% above this industry median. Based on the distribution chart, Jinhai Medical Technology ranks #532 out of 533 companies in the Conglomerates industry, which is in the bottom quartile relative to peers. Overall, Jinhai Medical Technology has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jinhai Medical Technology's PB Ratio compare to RHI and KFY?
According to the Conglomerates industry distribution chart, Jinhai Medical Technology ranks #532 out of 533 companies for PB Ratio. This places Jinhai Medical Technology in the lower half of its industry. The industry median PB Ratio is 1.06. Jinhai Medical Technology's value of 100.75 is 9404.7% above this benchmark. Historically, Jinhai Medical Technology's own PB Ratio has ranged from 3.86 to 111.64 over the past decade. While the company's 10-year median is 18.57 vs. the industry median of 1.06, Jinhai Medical Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Conglomerates company?
The median PB Ratio among Conglomerates companies is 1.06, based on 533 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jinhai Medical Technology's current PB Ratio of 100.75 is 9404.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jinhai Medical Technology and its competitors. For the Conglomerates industry, the median PB Ratio is 1.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jinhai Medical Technology's current PB Ratio is 100.75, which is 443% above median its own 10-year median of 18.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jinhai Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, Jinhai Medical Technology (HKSE:02225) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$1.41, compared to a current price of HK$6.05 — trading 328.7% above its estimated fair value. The current PB Ratio is 100.75, which is 443% above median its 10-year median of 18.57 and 9404.7% above the Conglomerates industry median of 1.06. Jinhai Medical Technology's overall GF Score™ is 61/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Jinhai Medical Technology (HKSE:02225), the current PB Ratio is 100.75 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jinhai Medical Technology (HKSE:02225) Overvalued in 2026?
Based on GuruFocus' analysis, Jinhai Medical Technology stock appears to be overvalued.
The current stock price of HK$6.05 is trading 328.7% above its estimated GF Value™ of HK$1.41.
GuruFocus considers Jinhai Medical Technology to be Significantly Overvalued.
Key valuation signals for HKSE:02225:
PB Ratio: 100.75 (443% above median its 10-year median of 18.57)
GF Value™: HK$1.41 vs. price of HK$6.05 (328.7% above fair value)
Industry Position: 9404.7% above the Conglomerates median (#532 of 533)
No single metric tells the full story. See the HKSE:02225 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jinhai Medical Technology Ltd is an investment holding company. Along with its subsidiaries, it is principally engaged in providing medical equipment in China and manpower outsourcing and ancillary services to building and construction contractors in Singapore. The group also provides IT services, construction ancillary services (which comprise warehousing, cleaning, and building maintenance works), and dormitory services in Singapore. It generates maximum revenue from the sale of minimally invasive surgery solutions, medical products, and related services in the People's Republic of China.
61GF Score
Get the complete analysis for HKSE:02225
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02225 has been successfully added to your 
